Summary

The Global Herpes Zoster Infection Treatment Market was valued at USD 248.92 million in 2024 and is expected to experience strong growth during the forecast period, with a compound annual growth rate (CAGR) of 3.89%, reaching USD 374.99 million by 2030. This market has experienced significant growth and transformation in recent years, driven by factors such as an aging population, increased awareness of herpes zoster infection, and ongoing advancements in medical research and treatment options.
Herpes zoster, also known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus (VZV), which initially causes chickenpox. It typically presents as a painful rash and blisters and can lead to long-term complications if not effectively managed. As a result, the demand for herpes zoster infection treatments has surged, fueling market expansion. According to the World Health Organization (WHO), shingles is a painful condition caused by the reactivation of VZV, and while anyone who has had chickenpox can develop shingles, it is more common in adults aged 50 and older.
One of the key drivers of the global herpes zoster infection treatment market is the aging population, as older individuals are more prone to VZV reactivation due to weakened immune systems. Increasing awareness of the condition, its potential complications, and the availability of effective treatments have led to earlier medical interventions, further propelling market growth.
Key Market Drivers
Rising Aging Population
As individuals age, their immune systems weaken, making them more susceptible to VZV reactivation. This increased vulnerability among the elderly population has led to a rise in shingles cases globally. For example, according to WHO 2024 statistics, the global population aged 60 and over will grow from 1 billion in 2020 to 1.4 billion by 2030, with those aged 80 and older projected to triple to 426 million by 2050. With a larger percentage of the global population entering their senior years, the incidence of herpes zoster infections has substantially increased.
Older adults with shingles often experience severe pain, discomfort, and complications, including postherpetic neuralgia (PHN), a persistent and debilitating pain condition. This heightened susceptibility, coupled with the potential severity of the infection, has driven demand for effective treatment options. Additionally, older individuals are generally more health-conscious and proactive about seeking medical care, which further accelerates the demand for herpes zoster treatments.
Key Market Challenges
High Treatment Costs
Despite significant growth, one of the major challenges facing the Global Herpes Zoster Infection Treatment Market is the high cost of treatment. Herpes zoster, or shingles, is a painful viral infection that requires antiviral medications, pain management drugs, and sometimes vaccines. These treatments can be costly, making them inaccessible to many patients, especially those without comprehensive healthcare coverage, resulting in delayed or inadequate care.
The cost of treatment includes antiviral medications like acyclovir, valacyclovir, and famciclovir, which are essential in reducing the severity and duration of shingles symptoms but are often expensive. Pain management medications, such as opioids and anti-inflammatory drugs, are also a critical aspect of treatment, adding to the overall cost burden. Additionally, while new pain management techniques and therapies are effective, they may not be readily available or covered by insurance plans, further increasing the financial burden on patients.
Key Market Trends
Expanding Access to Healthcare
Expanding access to healthcare services has become a crucial driver for the growth of the Global Herpes Zoster Infection Treatment Market. Timely medical intervention is critical for effectively managing herpes zoster, and improved access to healthcare services is enabling more individuals to receive necessary treatments. As healthcare systems evolve, investments are being made to enhance infrastructure and establish clinics, hospitals, and primary care centers in underserved areas, making healthcare more accessible to a wider population.
The rise of telemedicine and telehealth services has also expanded healthcare access for shingles patients. Remote consultations allow individuals to receive timely advice, diagnoses, and prescriptions, which improves overall management of herpes zoster infections. Additionally, these services help overcome geographical barriers, particularly in regions with limited access to healthcare facilities.
Improved healthcare access has led to increased awareness about herpes zoster, its symptoms, and the importance of early diagnosis and treatment. As individuals become more informed, they are more likely to seek medical attention when they experience symptoms, further boosting market growth. Governments and non-governmental organizations are also introducing initiatives to subsidize healthcare costs or provide financial assistance programs, reducing the financial burden on patients and ensuring access to essential medications and vaccines for those with limited financial resources.
Key Market Players
• GSK plc.
• Bausch Health Companies Inc.
• Renata Limited
• Novan, Inc.
• Teva Pharmaceuticals USA, Inc.
• Pfizer Inc.
• Apotex Inc.
• Sandoz Canada Inc.
• Novartis Pharmaceuticals Corporation
Report Scope:
In this report, the Global Herpes Zoster Infection Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Herpes Zoster Infection Treatment Market, By Treatment Type:
o Prescription Treatment
o Supporting Treatment
• Herpes Zoster Infection Treatment Market, By Route of administration:
o Oral
o Intravenous
o Others
• Herpes Zoster Infection Treatment Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Herpes Zoster Infection Treatment Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Herpes Zoster Infection Treatment Market.
Available Customizations:
Global Herpes Zoster Infection Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Herpes Zoster Infection Treatment Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Treatment Type (Prescription Treatment, Supporting Treatment)
4.2.2. By Route of Administration (Oral, Intravenous, Others)
4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Treatment Type
4.3.2. By Treatment
4.3.3. By Route of Administration
4.3.4. By Distribution Channel
4.3.5. By Region
5. Asia Pacific Herpes Zoster Infection Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type
5.2.2. By Route of Administration
5.2.3. By Distribution Channel
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Herpes Zoster Infection Treatment Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Treatment Type
5.3.1.2.2. By Treatment
5.3.1.2.3. By Route of Administration
5.3.1.2.4. By Distribution Channel
5.3.2. India Herpes Zoster Infection Treatment Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Treatment Type
5.3.2.2.2. By Route of Administration
5.3.2.2.3. By Distribution Channel
5.3.3. Australia Herpes Zoster Infection Treatment Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Treatment Type
5.3.3.2.2. By Route of Administration
5.3.3.2.3. By Distribution Channel
5.3.4. Japan Herpes Zoster Infection Treatment Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Treatment Type
5.3.4.2.2. By Route of Administration
5.3.4.2.3. By Distribution Channel
5.3.5. South Korea Herpes Zoster Infection Treatment Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Treatment Type
5.3.5.2.2. By Route of Administration
5.3.5.2.3. By Distribution Channel
6. Europe Herpes Zoster Infection Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Herpes Zoster Infection Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Germany Herpes Zoster Infection Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Spain Herpes Zoster Infection Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
6.3.4. Italy Herpes Zoster Infection Treatment Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Treatment Type
6.3.4.2.2. By Route of Administration
6.3.4.2.3. By Distribution Channel
6.3.5. United Kingdom Herpes Zoster Infection Treatment Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Treatment Type
6.3.5.2.2. By Route of Administration
6.3.5.2.3. By Distribution Channel
7. North America Herpes Zoster Infection Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By Distribution Channel
7.2.3. By Route of Administration
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Herpes Zoster Infection Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. Mexico Herpes Zoster Infection Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. Canada Herpes Zoster Infection Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
8. South America Herpes Zoster Infection Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Herpes Zoster Infection Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. Argentina Herpes Zoster Infection Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Colombia Herpes Zoster Infection Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
9. Middle East and Africa Herpes Zoster Infection Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Herpes Zoster Infection Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. Saudi Arabia Herpes Zoster Infection Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. UAE Herpes Zoster Infection Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Herpes Zoster Infection Treatment Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. GSK plc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Bausch Health Companies Inc.
14.3. Renata Limited
14.4. Novan, Inc.
14.5. Teva Pharmaceuticals USA, Inc.
14.6. Pfizer Inc.
14.7. Apotex Inc.
14.8. Sandoz Canada Inc.
14.9. Novartis Pharmaceuticals Corporation.
15. Strategic Recommendations
16. About Us & Disclaimer